Skip Navigation

News & Resources

 

Subscribe to NHLBI Press Releases
April 18, 2017

Researchers discover mitochondrial “circuit breaker” that protects heart from damage

A team of scientists from the National Institutes of Health has discovered biological mechanisms that appear to prevent damage to the heart muscle’s “power grid,” the network of mitochondrial circuits that provide energy to cells. One of those mechanisms, the researchers found, acts much like a circuit breaker, allowing energy to continue moving throughout the heart muscle cells even when individual components of those cells—the mitochondria—have been damaged.

April 6, 2017

NHLBI Stem Cell Consortium Provides New Insights into Genetics of Heart Disease, Other Conditions

WHAT:  A group of NIH-funded scientists has published the first studies using the largest, most diverse stem cell collection of its kind ever made available to researchers. The results provide fresh insights into the genetic underpinnings of common conditions such as cardiovascular disease, high blood pressure, diabetes, and sickle cell disease, which take a heavy toll on American lives and resources.

Subscribe to NHLBI In The News
April 27, 2017 : Genetic Engineering & Biotechnology News

Researchers have identified a potential new target in the mitochondria (the cell's powerhouse) for fighting heart disease.  In studies using mice, the scientists showed that the exit of calcium from mitochondria in heart cells plays a key role in normal heart function and that boosting calcium transport might help limit the severity of heart disease. Their study, published in Nature, was supported by NHLBI.  

April 20, 2017 : The New England Journal of Medicine

A study conducted by NHLBI researchers found that the drug eltrombopag improves the response to treatment in patients with severe aplastic anemia. “Eltrombopag plus standard immunosuppressive therapy appeared to increase the overall response rate and substantially increase the frequency, speed and robustness of hematologic recovery in patients with SAA compared to historical controls,” said NHLBI researcher and the study’s lead author, Danielle Townsley, MD. The findings appear in the The New England Journal of Medicine.

Healio: Eltrombopag shows promise as first treatment for severe aplastic anemia

PharmaTimes: Data back first-line use of Novartis’ eltrombopag in SAA

Hematology Times: Combo improves response rates in treatment-naïve SAA

RareDR: Should Second-line Aplastic Anemia Drug Be a First-line Option?

GlobeNewswire: NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia